An earlier general systematic review on the neuroprotective role of GLP-1, which included both clinical and preclinical trials in PD, Alzheimer’s disease (AD), mood disorders, and other conditions, concluded—based on preclinical data—that GLP-1 has a substantial role in neuroprotection [62]. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.